Conferences
EAU 2024: No Need for TURBT, VI-RADS Makes the Diagnosis
April 5, 2024
EAU 2024: Controversies in Initial Staging for Renal Cell Cancer: Biopsy and Pathology Is the Solution
April 5, 2024
EAU 2024: Initial Staging in Bladder Cancer: Histologic Subtype, Molecular Phenotype, and Biomarkers Are Enough
April 5, 2024
EAU 2024: The SPARC Initiative (Standardized PSMA PET Analysis and Reporting Consensus)
April 5, 2024
EAU 2024: The PSMA M1a Positive Patient: Treat as M1
April 5, 2024
EAU 2024: Controversies in Initial Staging for Renal Cell Cancer: Evaluation with Molecular Imaging Is the Way to Go
April 5, 2024
EAU 2024: Controversies in Initial Staging for Bladder Cancer: TURBT Is Mandatory Before Any Treatment
April 5, 2024
EAU 2024: The PSMA M1a Positive Patient: Treat as M0
April 5, 2024
SESAUA 2024: Time Interval Between Radium-223 Therapy and 177Lu-PSMA Treatment for mCRPC and Outcomes in the RALU Study
March 25, 2024
SESAUA 2024: Screening with PSA and MRI: Yearly Trends by PI-RADS and Race Shows Stable Diagnosis of NCCN Very Low Risk Disease
March 23, 2024
SESAUA 2024: Association of PSA Response and Overall Survival in Patients with mHSPC: Results from the Phase 3 ARASENS Trial
March 23, 2024